Simultaneous evaluation of treatment efficacy and toxicity for bispecific T‐cell engager therapeutics in a humanized mouse model
The FASEB Journal · 2023
DOI: 10.1096/fj.202300040r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Jiwon Yang und 15 weiteren Autor:innen. Beteiligte Einrichtung: The Jackson Laboratory, Sacramento, California, USA. Hauptthemen laut MEDLINE: Leukocytes, Mononuclear, T-Lymphocytes. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Department of Health.
Abstract (Originalsprache)
Immuno‐oncology (IO)‐based therapies such as checkpoint inhibitors, bi‐specific antibodies, and CAR‐T‐cell therapies have shown significant success in the treatment of several cancer indications. However, these therapies can result in the development of severe adverse events, including cytokine release syndrome (CRS). Currently, there is a paucity of in vivo models that can evaluate dose‐response relationships for both tumor control and CRS‐related safety issues. We tested an in vivo PBMC humanized mouse model to assess both treatment efficacy against specific tumors and the concurrent cytokine release profiles for individual human donors after treatment with a CD19xCD3 bispecific T‐cell engager (BiTE). Using this model, we evaluated tumor burden, T‐cell activation, and cytokine release in response to bispecific T‐cell‐engaging antibody in humanized mice generated with different PBMC donors. The results show that PBMC engrafted NOD‐ scid Il2rg null mice lacking expression of mouse MHC class I and II (NSG‐MHC‐DKO mice) and implanted with a tumor xenograft predict both efficacy for tumor control by CD19xCD3 BiTE and stimulated cytokine release. Moreover, our findings indicate that this PBMC‐engrafted model captures variability among donors for tumor control and cytokine release following treatment. Tumor control and cytokine release were reproducible for the same PBMC donor in separate experiments. The PBMC humanized mouse model described here is a sensitive and reproducible platform that identifies specific patient/cancer/therapy combinations for treatment efficacy and development of complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Jackson Laboratory, Sacramento, California, USA.
- The Jackson Laboratory, Bar Harbor, Massachusetts, USA.
- Program in Molecular Medicine, Diabetes Center of Excellence, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Biotherapeutics Division, National Institute for Biological Standards and Control, Hertfordshire, UK.
- Non Clinical Safety, GlaxoSmithKline plc, Collegeville, Pennsylvania, USA.
- NonClinical Safety and Pathobiology, Gilead Sciences Inc', Foster City, California, USA.
ORCID-Profile: Jiwon Yang, Michael A Brehm
Förderung
- NCI NIH HHS
- NIH HHS
- Department of Health
- NIDDK NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Yang, J., Jiao, J., Draheim, K. M., Yang, G., Yang, H., Yao, L. C., Shultz, L. D., Greiner, D. L., Rajagopal, D., Vessillier, S., Maier, C. C., Mohanan, S., Cai, D., Cheng, M., Brehm, M. A., & Keck, J. G. (2023). Simultaneous evaluation of treatment efficacy and toxicity for bispecific T‐cell engager therapeutics in a humanized mouse model. The FASEB Journal. https://doi.org/10.1096/fj.202300040r
Vancouver
Yang J, Jiao J, Draheim KM, Yang G, Yang H, Yao LC, et al. Simultaneous evaluation of treatment efficacy and toxicity for bispecific T‐cell engager therapeutics in a humanized mouse model. The FASEB Journal. 2023. doi:10.1096/fj.202300040r
BibTeX
@article{Yang2023,
author = {Yang, Jiwon and Jiao, Jing and Draheim, Kyle M and Yang, Guoxiang and Yang, Hongyuan and Yao, Li-Chin and Shultz, Leonard D and Greiner, Dale L and Rajagopal, Deepa and Vessillier, Sandrine and Maier, Curtis C and Mohanan, Sunish and Cai, Danying and Cheng, Mingshan and Brehm, Michael A and Keck, James G},
title = {Simultaneous evaluation of treatment efficacy and toxicity for bispecific T‐cell engager therapeutics in a humanized mouse model},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202300040r}
}
EUVIMED